Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Brain Cancer
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Short Treatment Delays May Not Hamper Survival in Glioblastoma
For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Fewer Children Enrolling in Pediatric Cancer Trials
Adolescent and young adult cancer patients underrepresented in clinical trials.
Pediatric Brain Cancer Outcomes Worse for Black, Hispanic Patients
Disparities for disease severity not seen at diagnosis, meaning postdiagnosis factors may affect outcome.
Pedmark Receives Priority Review for Prevention of Cisplatin-Induced Ototoxicity
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
Time to Radiotherapy After Glioblastoma Resection Affects Survival Outcomes
A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Next post in General Oncology
